Galectina-3 Associada a Formas Graves e Mortalidade em Longo Prazo em Pacientes com Doença de Chagas

Fernandes, Fábio; Moreira, Carlos Henrique Valente; Oliveira, Léa Campos de; Souza-Basqueira, Marcela de; Ianni, Bárbara Maria; Lorenzo, Claudia; Ramires, Felix José Alvarez; Nastari, Luciano; Cunha‐Neto, Edécio; Ribeiro, Antônio Luiz Pinho; Lópes, Renato D.; Keating, Sheila M.; Sabino, Éster Cerdeira; Mady, Charles

doi:10.36660/abc.20190403

Cited by 6 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of the Gal-3 pathway, which is currently one of the most promising novels therapeutic targets for managing myocardial fibrosis, may prevent cardiac remodeling and dysfunction In the preclinical study ( 54 ). Furthermore, previous clinical research has shown that Gal-3 as a biomarker is correlated with CV disease risk stratification ( 55 ) or adverse prognosis ( 52 , 56 ). In the field of HF, Gal-3 has proven to provide additive diagnostic and prognostic value ( 57 , 58 ) and was recommended as a novel biological indicator for the risk stratification of HF at the 2013 American College of Cardiology Foundation (ACCF) /American Heart Association (AHA) ( 59 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis

Shi¹,

Dong

Liu

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundHeart failure with preserved ejection fraction (HFpEF) is an increasing public health concern. Currently, data regarding the clinical application value of plasma Galectin-3 (Gal-3) in HFpEF are contradictory. Therefore, we performed the following meta-analysis to appraise the clinical implications of serum Gal-3 in HFpEF, including its capacity to predict new-onset disease, long-term unfavorable endpoints, and the degree of cardiac structural abnormality and left ventricular diastolic dysfunction (LVDD).MethodsPubMed, Embase, Scopus, and Web of Science were retrieved exhaustively from their inception until November 30, 2021, to obtain studies assessing the correlation between plasma Gal-3 and the clinical features of HFpEF (new-onset HFpEF, adverse outcomes, and echocardiographic parameters related to abnormal cardiac structure and LVDD).ResultsA total of 24 papers containing 27 studies were ultimately included in the present research. The results of the meta-analysis revealed that high plasma Gal-3 levels are strongly associated with the following clinical characteristics of HFpEF: (i) the increased risk of new-onset HFpEF (HR: 1.11; 95% CI: 1.04-1.19; p = 0.910, I2 = 0%; P = 0.002); (ii) the high risk of adverse outcomes of HFpEF patients [all-cause death (HR: 1.55; 95% CI: 1.27-1.87; p = 0.138, I2 = 42%; P = 0.000) and the composite events [all-cause death and HF hospitalization (HR: 1.50; 95% CI: 1.30-1.74; p = 0.001, I2 = 61%; P = 0.000) or cardiovascular (CV) death and HF hospitalization (HR: 1.71; 95% CI: 1.51-1.94; p = 0.036, I2 = 58%; P = 0.000)]; (iii) echocardiographic indices [E/e ratio (r: 0.425, 95% CI: 0.184-0.617; p = 0.000, I2 = 93%; P = 0.001) and DT (r: 0.502, 95% CI: 0.061-0.779; p = 0.001 I2 = 91%; P = 0.027)].ConclusionsPlasma Gal-3 might be employed as an additional predictor for new-onset HFpEF, the adverse prognosis in HFpEF patients (all-cause death, the composite endpoints of all-cause death and HF hospitalization or CV death and HF hospitalization), and the severity of LVDD in HFpEF populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis

Shi¹,

Dong

Liu

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

Galectin-3 (Gal-3) and the tissue inhibitor of matrix metalloproteinase (TIMP-2) as potential biomarkers for the clinical evolution of chronic Chagas cardiomyopathy

Menezes,

de Oliveira,

Barbosa

et al. 2024

Acta Tropica

View full text Add to dashboard Cite

Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review

Chaves

Oliveira

Guimarães

et al. 2022

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Chronic Chagas Cardiomyopathy (CCC) is the most prevalent type of myocarditis and the main clinical form of the Chagas disease, which has peculiarities such as focal inflammation, structural derangement, hypertrophy, dilation, and intense reparative fibrosis. Many cellular compounds contribute to CCC development. Galectin-3 is a partaker in inflammation and contributes to myocardial fibrosis formation. Some studies showed the connection between Galectin-3 and fibrosis in Chagas disease but are still inconclusive on the guidance for the early implementation of pharmacological therapy. This systematic review evaluated Galectin-3 as a biomarker for fibrosis intensity in CCC. Two independent reviewers have searched five databases (PubMed, EMBASE, Cochrane Library, Scopus, and Lilacs), using the following search terms: galectin-3, biomarkers, fibrosis, Chagas cardiomyopathy, and Chagas disease. Overall, seven studies met the inclusion criteria and made up this review. There were four trials conducted through animal model experiments and three trials with humans. Experimental data in mice indicate an association between Galectin-3 expression and fibrosis in CCC (75% of studies). Data from human studies showed no direct connection between myocardial fibrosis and Galectin-3 expression (80% of studies). Thus, human findings do not provide significant evidence indicating that Galectin-3 is related to fibrosis formation in Chagas disease. Based on the analyzed studies, it is suggested that Galectin-3 might not be a good fibrosis marker in CCC.

show abstract

Galectina-3 Associada a Formas Graves e Mortalidade em Longo Prazo em Pacientes com Doença de Chagas

Cited by 6 publications

References 31 publications

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis

Galectin-3 (Gal-3) and the tissue inhibitor of matrix metalloproteinase (TIMP-2) as potential biomarkers for the clinical evolution of chronic Chagas cardiomyopathy

Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review

Contact Info

Product

Resources

About